T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones
2026/01
29
An Interview with Chairman Tse-Wen Chang: A Journey Through Science and Entrepreneurship
2026/01
21
Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from "Maltose" to "Aqueous Solution"
2025/12
26
Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential
2025/12
08
In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology
2025/11
14